Upadacitinib (Standard)
Based on 1 publication(s) in Google Scholar
Upadacitinib (Standard) is the analytical standard of Upadacitinib. This product is intended for research and analytical applications. Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.72%
- CAS No.: 1310726-60-3
- 화학식: C17H19F3N6O
- 분자량:380.37
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- 순도&문서
-
Help & FAQs
-
HY-107429
AbrocitinibJAK1 Inhibitor -
HY-117287
DeucravacitinibTYK2 Inhibitor -
HY-15315
BaricitinibJAK1/2 Inhibitor -
HY-40354
TofacitinibJAK1/JAK3 Inhibitor -
HY-18300
FilgotinibJAK1 Inhibitor -
HY-15315R
Baricitinib (Standard)JAK1/2 Inhibitor -
HY-19569
UpadacitinibJAK1 Inhibitor -
HY-10409
FedratinibJAK2 Inhibitor -
HY-50858
Ruxolitinib phosphateJAK1/2 Inhibitor -
HY-40354R
Tofacitinib (Standard)Reference Standard -
HY-50856R
Ruxolitinib (Standard)JAK1/2 Inhibitor -
HY-16379
PacritinibJAK2/FLT3 Inhibitor
Publications Citing Use of MedChemExpress (MCE) Upadacitinib (Standard)
More
Product Information
Information
신청
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 1310726-60-3
-
Appearance Solid
-
분자량 380.37
-
화학식 C17H19F3N6O
-
Color White to off-white
-
SMILES
O=C(N1C[C@@H](CC)[C@@H](C2=CN=C3C=NC(NC=C4)=C4N32)C1)NCC(F)(F)F
-
Synonyms
ABT-494 (Standard)
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
J Pharmacol Toxicol Methods
Development and validation of a sensitive LC-MS/MS assay for determination of upadacitinib in human plasma and its application in patients with inflammatory bowel disease. [Abstract]2025 Feb:131:107581. PMID: 39862900
순도&문서
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Nakayamada S, et al. Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis. BioDrugs. 2016 Oct;30(5):407-419. [Content Brief]
[3]. Parmentier JM, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018 Aug 28;2:23. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Upadacitinib (Standard) Related Classifications
HY-19569R Related Classifications
Powered by Bioz